The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Among recipients with HIV, kidney transplantation from donors with HIV is noninferior to that from donors without HIV.

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...

Preventing Perinatal Transmission of HIV. National Library of Medicine. HIV and pregnancy. HIV.gov. HIV Treatments: The Basics. National Library of Medicine. HIV in Women. HIV.gov. HIV and Birth ...

Unlike oral PrEP treatments, which are taken daily, the drug is administered at six-month intervals and is the longest acting injectable produced to date. In a late-stage trial, lenacapavir reduced ...